Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148337 | PMC |
| http://dx.doi.org/10.2490/prm.20240020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A Meta-Analysis.
Ophthalmol Ther
December 2024
ESiOR Oy, Kuopio, Finland.
Introduction: Diffractive trifocal intraocular lenses (IOLs) provide good vision at distance, intermediate, and near, but can also cause positive dysphotopsias. This meta-analysis pooled published evidence on visual disturbances after bilateral implantation of the PanOptix (TFNTXX) IOL for patients undergoing cataract surgery.
Method: A systematic literature search was conducted in PubMed and congress presentations from April 2021 to December 2022 to identify studies with patient-reported outcomes on the incidence of visual disturbances (starbursts, halos, glare) post bilateral implantation of PanOptix IOL during cataract surgery.
Patterns and predictors of multiple sclerosis phenotype transition.
Brain Commun
November 2024
The Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital-Rigshospitalet Glostrup, 2600 Glostrup, Denmark.
Currently, there are limited therapeutic options for patients with non-active secondary progressive multiple sclerosis. Therefore, real-world studies have investigated differences between patients with relapsing-remitting multiple sclerosis, non-active secondary progressive multiple sclerosis and active secondary progressive multiple sclerosis. Here, we explore patterns and predictors of transitioning between these phenotypes.
View Article and Find Full Text PDFEffectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-α in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis.
United European Gastroenterol J
December 2024
Institute of Clinical Molecular Biology and Clinic for Internal Medicine, Kiel University, Kiel, Germany.
Background: Vedolizumab is approved for the treatment of moderately to severely active Crohn's disease (CD). Real-world evidence is essential for understanding the effectiveness and benefit-risk profile of vedolizumab outside clinical trial settings.
Objective: To identify, systematically review and assess the real-world effectiveness and treatment persistence of vedolizumab in patients with CD, particularly over long-term follow-up periods and among populations with differing treatment experience, and to compare with the treatment persistence of anti-tumour necrosis factor (TNF)-α treatment.
Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study.
Cancers (Basel)
December 2024
Phase IV Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy.
Background/objectives: HER2-positive breast cancer (HER2BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been established as the standard of care in the adjuvant setting for HER2BC patients who do not obtain pCR. The ATD study aimed to evaluate the real-world tolerability of T-DM1 in this setting.
View Article and Find Full Text PDFPopulation-level impact of weight loss on predicted healthcare spending and the incidence of obesity-related outcomes in the Asia-Pacific region: a modelling study.
BMC Glob Public Health
October 2024
Department of Physiology, Faculty of Biomedical and Psychological Sciences, Monash Biomedicine Discovery Institute, Clayton, Australia.
Article Synopsis
- The Asia-Pacific region faces a significant challenge with obesity, which is linked to various health issues and rising medical costs; a hypothetical 10% weight loss could lead to significant savings over the next decade.
- Using an epidemiological-economic model, the study assessed current and future obesity-related health costs and problems in Australia, South Korea, Thailand, and India, revealing that costs could increase dramatically if no action is taken.
- A 10% weight reduction could save billions in medical expenses by 2032 while reducing the incidence of obesity-related comorbidities, highlighting the need for effective policies to support obesity management in the region.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!